-
1
-
-
13744257860
-
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
-
Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 97 (2005) 188-194
-
(2005)
J. Natl. Cancer Inst.
, vol.97
, pp. 188-194
-
-
Mauri, D.1
Pavlidis, N.2
Ioannidis, J.P.3
-
2
-
-
0024987463
-
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
-
Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J. Natl. Cancer Inst. 82 (1990) 1539-1545
-
(1990)
J. Natl. Cancer Inst.
, vol.82
, pp. 1539-1545
-
-
Bonadonna, G.1
Veronesi, U.2
Brambilla, C.3
Ferrari, L.4
Luini, A.5
Greco, M.6
-
3
-
-
17444454498
-
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
-
Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R.G., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15 (1997) 2483-2493
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 2483-2493
-
-
Fisher, B.1
Brown, A.2
Mamounas, E.3
Wieand, S.4
Robidoux, A.5
Margolese, R.G.6
-
4
-
-
27944503994
-
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
-
Amat S., Abrial C., Penault-Llorca F., Delva R., Bougnoux P., Leduc B., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast. Cancer Res. Treat. 94 (2005) 255-263
-
(2005)
Breast. Cancer Res. Treat.
, vol.94
, pp. 255-263
-
-
Amat, S.1
Abrial, C.2
Penault-Llorca, F.3
Delva, R.4
Bougnoux, P.5
Leduc, B.6
-
5
-
-
0035751675
-
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18
-
Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 30 (2001) 96-102
-
(2001)
J. Natl. Cancer Inst. Monogr.
, vol.30
, pp. 96-102
-
-
Wolmark, N.1
Wang, J.2
Mamounas, E.3
Bryant, J.4
Fisher, B.5
-
6
-
-
0033050164
-
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
-
Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17 (1999) 460-469
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 460-469
-
-
Kuerer, H.M.1
Newman, L.A.2
Smith, T.L.3
Ames, F.C.4
Hunt, K.K.5
Dhingra, K.6
-
7
-
-
0031926839
-
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
-
Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16 (1998) 2672-2685
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 2672-2685
-
-
Fisher, B.1
Bryant, J.2
Wolmark, N.3
Mamounas, E.4
Brown, A.5
Fisher, E.R.6
-
8
-
-
0036498789
-
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
-
Rouzier R., Extra J.M., Klijanienko J., Falcou M.C., Asselain B., Vincent-Salomon A., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J. Clin. Oncol. 20 (2002) 1304-1310
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 1304-1310
-
-
Rouzier, R.1
Extra, J.M.2
Klijanienko, J.3
Falcou, M.C.4
Asselain, B.5
Vincent-Salomon, A.6
-
9
-
-
33644529487
-
Outcome after pathologic complete eradication of cytologically proven breast,cancer axillary node metastases following primary chemotherapy
-
Hennessy B.T., Hortobagyi G.N., Rouzier R., Kuerer H., Sneige N., Buzdar A.U., et al. Outcome after pathologic complete eradication of cytologically proven breast,cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23 (2005) 9304-9311
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 9304-9311
-
-
Hennessy, B.T.1
Hortobagyi, G.N.2
Rouzier, R.3
Kuerer, H.4
Sneige, N.5
Buzdar, A.U.6
-
10
-
-
33646375742
-
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
-
Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24 (2006) 1940-1949
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1940-1949
-
-
Kaufmann, M.1
Hortobagyi, G.N.2
Goldhirsch, A.3
Scholl, S.4
Makris, A.5
Valagussa, P.6
-
11
-
-
33644546434
-
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
-
Kuroi K., Toi M., Tsuda H., Kurosumi M., and Akiyama F. Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed. Pharmacother. 59 (2005) s387-s392
-
(2005)
Biomed. Pharmacother.
, vol.59
-
-
Kuroi, K.1
Toi, M.2
Tsuda, H.3
Kurosumi, M.4
Akiyama, F.5
-
12
-
-
33646445341
-
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocol B-27
-
Bear H.D., Anderson S., Smith R.E., Geyer Jr. C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel project protocol B-27. J. Clin. Oncol. 24 (2006) 2019-2027
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 2019-2027
-
-
Bear, H.D.1
Anderson, S.2
Smith, R.E.3
Geyer Jr., C.E.4
Mamounas, E.P.5
Fisher, B.6
-
13
-
-
5144219905
-
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
-
Colleoni M., Viale G., Zahrieh D., Pruneri G., Gentilini O., Veronesi P., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10 (2004) 6622-6628
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 6622-6628
-
-
Colleoni, M.1
Viale, G.2
Zahrieh, D.3
Pruneri, G.4
Gentilini, O.5
Veronesi, P.6
-
14
-
-
0037103104
-
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18
-
Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., and Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 (2002) 681-695
-
(2002)
Cancer
, vol.95
, pp. 681-695
-
-
Fisher, E.R.1
Wang, J.2
Bryant, J.3
Fisher, B.4
Mamounas, E.5
Wolmark, N.6
-
15
-
-
0037428704
-
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
-
Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br. J. Cancer 88 (2003) 406-412
-
(2003)
Br. J. Cancer
, vol.88
, pp. 406-412
-
-
Faneyte, I.F.1
Schrama, J.G.2
Peterse, J.L.3
Remijnse, P.L.4
Rodenhuis, S.5
van de Vijver, M.J.6
-
16
-
-
33644973070
-
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
-
Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24 (2006) 1037-1044
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1037-1044
-
-
Guarneri, V.1
Broglio, K.2
Kau, S.W.3
Cristofanilli, M.4
Buzdar, A.U.5
Valero, V.6
-
17
-
-
2642585065
-
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
-
Smith I.E., A'Hern R.P., Coombes G.A., Howell A., Ebbs S.R., Hickish T.F., et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann. Oncol. 15 (2004) 751-758
-
(2004)
Ann. Oncol.
, vol.15
, pp. 751-758
-
-
Smith, I.E.1
A'Hern, R.P.2
Coombes, G.A.3
Howell, A.4
Ebbs, S.R.5
Hickish, T.F.6
-
18
-
-
24044515003
-
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trial (TOPIC 2)
-
Chua S., Smith I.E., A'Hern R.P., Coombes G.A., Hickish T.F., Robinson A.C., et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trial (TOPIC 2). Ann. Oncol. 16 (2005) 1435-1441
-
(2005)
Ann. Oncol.
, vol.16
, pp. 1435-1441
-
-
Chua, S.1
Smith, I.E.2
A'Hern, R.P.3
Coombes, G.A.4
Hickish, T.F.5
Robinson, A.C.6
-
19
-
-
4243252937
-
Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial
-
abs 254
-
Pelissier P., Delaloge S., Mathieu M.C., Jeanblanc G., Petit T., Eymard J.C., et al. Intensified anthracyclin doses do not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer (BC): results of a multicenter randomized trial. Proc. Am. Soc. Clin. Oncol. (2002) abs 254
-
(2002)
Proc. Am. Soc. Clin. Oncol.
-
-
Pelissier, P.1
Delaloge, S.2
Mathieu, M.C.3
Jeanblanc, G.4
Petit, T.5
Eymard, J.C.6
-
20
-
-
0035253733
-
-
French Adjuvant Study Group, Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial, J. Clin. Oncol. 19 (3) (2001) 602-611.
-
-
-
-
21
-
-
0032751112
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
-
Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N.L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J. Clin. Oncol. 17 (1999) 3412-3417
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 3412-3417
-
-
Buzdar, A.U.1
Singletary, S.E.2
Theriault, R.L.3
Booser, D.J.4
Valero, V.5
Ibrahim, N.L.6
-
22
-
-
7044249032
-
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
-
Schneeweiss A., Huober J., Sinn H.P., von Fournier D., Rudlowski C., Beldermann F., et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. Eur. J. Cancer 40 (2004) 2432-2438
-
(2004)
Eur. J. Cancer
, vol.40
, pp. 2432-2438
-
-
Schneeweiss, A.1
Huober, J.2
Sinn, H.P.3
von Fournier, D.4
Rudlowski, C.5
Beldermann, F.6
-
23
-
-
24944535396
-
Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study
-
Conte P.F., Donati S., Gennari A., Guarneri V., Orlandini C., Rondini M., et al. Primary chemotherapy with Gemcitabine, Epirubicin and Taxol (GET) in operable breast cancer: a phase II study. Brit. J. Cancer 93 (2005) 406-411
-
(2005)
Brit. J. Cancer
, vol.93
, pp. 406-411
-
-
Conte, P.F.1
Donati, S.2
Gennari, A.3
Guarneri, V.4
Orlandini, C.5
Rondini, M.6
-
24
-
-
0037083497
-
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study
-
de Matteis A., Nuzzo F., D'Aiuto G., Labonia V., Landi G., Rossi E., et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94 (2002) 895-901
-
(2002)
Cancer
, vol.94
, pp. 895-901
-
-
de Matteis, A.1
Nuzzo, F.2
D'Aiuto, G.3
Labonia, V.4
Landi, G.5
Rossi, E.6
-
25
-
-
12144262655
-
Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer
-
Malhotra V., Dorr V.J., Lyss A.P., Anderson C.M., Westgate S., Reynolds M., et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin. Breast Cancer 5 (2004) 377-384
-
(2004)
Clin. Breast Cancer
, vol.5
, pp. 377-384
-
-
Malhotra, V.1
Dorr, V.J.2
Lyss, A.P.3
Anderson, C.M.4
Westgate, S.5
Reynolds, M.6
-
26
-
-
19944424117
-
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
-
Espinosa E., Morales S., Borrega P., Casas A., Madronal C., Machengs I., et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemoth. Pharm. 54 (2004) 546-552
-
(2004)
Cancer Chemoth. Pharm.
, vol.54
, pp. 546-552
-
-
Espinosa, E.1
Morales, S.2
Borrega, P.3
Casas, A.4
Madronal, C.5
Machengs, I.6
-
27
-
-
0036177015
-
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor
-
Wenzel C., Locker G.J., Schmidinger M., Rudas M., Taucher S., Gnant M.F., et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor. Anticancer Drugs 13 (2002) 67-74
-
(2002)
Anticancer Drugs
, vol.13
, pp. 67-74
-
-
Wenzel, C.1
Locker, G.J.2
Schmidinger, M.3
Rudas, M.4
Taucher, S.5
Gnant, M.F.6
-
28
-
-
10744227179
-
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
-
Ganem G., Tubiana-Hulin M., Fumoleau P., Combe M., Misset J.L., Vannetzel J.M., et al. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14 (2003) 1623-1628
-
(2003)
Ann. Oncol.
, vol.14
, pp. 1623-1628
-
-
Ganem, G.1
Tubiana-Hulin, M.2
Fumoleau, P.3
Combe, M.4
Misset, J.L.5
Vannetzel, J.M.6
-
29
-
-
0036860308
-
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group
-
Gogas H., Papadimitriou C., Kalofonos H.P., Bafaloukos D., Fountzilas G., Tsavdaridis D., et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann. Oncol. 13 (2002) 1737-1742
-
(2002)
Ann. Oncol.
, vol.13
, pp. 1737-1742
-
-
Gogas, H.1
Papadimitriou, C.2
Kalofonos, H.P.3
Bafaloukos, D.4
Fountzilas, G.5
Tsavdaridis, D.6
-
30
-
-
17944384873
-
Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer
-
Moliterni A., Tarenzi E., Capri G., Terenziani M., Bertuzzi A., Grasselli G., et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin. Oncol. S17 (1997) 10-14
-
(1997)
Semin. Oncol.
, vol.S17
, pp. 10-14
-
-
Moliterni, A.1
Tarenzi, E.2
Capri, G.3
Terenziani, M.4
Bertuzzi, A.5
Grasselli, G.6
-
31
-
-
0034493019
-
Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients
-
Bellino R., Cortese P., Danese S., De Sanctis C., Durando A., Genta F., Grio R., et al. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients. Anticancer Res. 29 (2000) 4825-4828
-
(2000)
Anticancer Res.
, vol.29
, pp. 4825-4828
-
-
Bellino, R.1
Cortese, P.2
Danese, S.3
De Sanctis, C.4
Durando, A.5
Genta, F.6
Grio, R.7
-
32
-
-
23544439804
-
Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicin vs fluorouracil + doxorubicin + cyclophosphamide
-
(abstr 159)
-
Semiglazov V.F., Bojok A.A., Arsumanov A.S., Ivanova O.A., Ivanov V.G., Semiglazov V.V., et al. Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicin vs fluorouracil + doxorubicin + cyclophosphamide. Breast Cancer Res. Treat. 7 (2002) S:52 (abstr 159)
-
(2002)
Breast Cancer Res. Treat.
, vol.7
-
-
Semiglazov, V.F.1
Bojok, A.A.2
Arsumanov, A.S.3
Ivanova, O.A.4
Ivanov, V.G.5
Semiglazov, V.V.6
-
33
-
-
21144439271
-
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study
-
Evans T.R., Yellowlees A., Foster E., Earl H., Cameron D.A., Hutcheon A.W., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J. Clin. Oncol. 23 (2005) 2988-2995
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2988-2995
-
-
Evans, T.R.1
Yellowlees, A.2
Foster, E.3
Earl, H.4
Cameron, D.A.5
Hutcheon, A.W.6
-
34
-
-
16644384267
-
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
-
Dieras V., Fumoleau P., Romieu G., Tubiana-Hulin M., Namer M., Mauriac L., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J. Clin. Oncol. 22 (2004) 4958-4965
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 4958-4965
-
-
Dieras, V.1
Fumoleau, P.2
Romieu, G.3
Tubiana-Hulin, M.4
Namer, M.5
Mauriac, L.6
-
35
-
-
16244365739
-
6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14
-
abs 553
-
Steger G.G., Kubista E., Hausmaninger H., Gnant M., Tausch C., Lang A., et al. 6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. Proc. Am. Soc. Clin. Oncol. 22 (2004) abs 553
-
(2004)
Proc. Am. Soc. Clin. Oncol.
, vol.22
-
-
Steger, G.G.1
Kubista, E.2
Hausmaninger, H.3
Gnant, M.4
Tausch, C.5
Lang, A.6
-
36
-
-
24044545225
-
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer
-
Reitsamer R., Peintinger F., Prokop E., and Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 168 (2005) 867-870
-
(2005)
Anticancer Drugs
, vol.168
, pp. 867-870
-
-
Reitsamer, R.1
Peintinger, F.2
Prokop, E.3
Hitzl, W.4
-
37
-
-
4444305144
-
A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC)
-
(abs 118)
-
Roumieu G., Tubiana-Hulin M., Fumoleau P., Namer M., Delva R., Guastalla J.P., et al. A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC). Ann. Oncol. 13 (2002) (abs 118)
-
(2002)
Ann. Oncol.
, vol.13
-
-
Roumieu, G.1
Tubiana-Hulin, M.2
Fumoleau, P.3
Namer, M.4
Delva, R.5
Guastalla, J.P.6
-
38
-
-
29344467956
-
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouraciland its effects on tumor response as preoperative therapy
-
Gianni L., Baselga J., Eiermann W., Guillem Porta V., Semiglazov V., Lluch A., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouraciland its effects on tumor response as preoperative therapy. Clin. Cancer Res. 11 (2005) 8715-8721
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 8715-8721
-
-
Gianni, L.1
Baselga, J.2
Eiermann, W.3
Guillem Porta, V.4
Semiglazov, V.5
Lluch, A.6
-
39
-
-
0037087562
-
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel
-
Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20 (2002) 1456-1466
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 1456-1466
-
-
Smith, I.C.1
Heys, S.D.2
Hutcheon, A.W.3
Miller, I.D.4
Payne, S.5
Gilbert, F.J.6
-
40
-
-
0036814394
-
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial
-
Heys S.D., Hutcheon A.W., Sarkar T.K., Ogston K.N., Miller I.D., Payne S., et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin. Breast Cancer 3 (2002) S69-S74
-
(2002)
Clin. Breast Cancer
, vol.3
-
-
Heys, S.D.1
Hutcheon, A.W.2
Sarkar, T.K.3
Ogston, K.N.4
Miller, I.D.5
Payne, S.6
-
41
-
-
19944426993
-
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
-
von Minckwitz G., Blohmer J.U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann. Oncol. 16 (2005) 56-63
-
(2005)
Ann. Oncol.
, vol.16
, pp. 56-63
-
-
von Minckwitz, G.1
Blohmer, J.U.2
Raab, G.3
Lohr, A.4
Gerber, B.5
Heinrich, G.6
-
42
-
-
0035425528
-
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
-
von Minckwitz G., Costa S.D., Raab G., Blohmer J.U., Eidtmann H., Hilfrich J., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J. Clin. Oncol. 19 (2001) 3506-3515
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3506-3515
-
-
von Minckwitz, G.1
Costa, S.D.2
Raab, G.3
Blohmer, J.U.4
Eidtmann, H.5
Hilfrich, J.6
-
43
-
-
24944542869
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
-
Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 23 (2005) 5983-5992
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5983-5992
-
-
Green, M.C.1
Buzdar, A.U.2
Smith, T.3
Ibrahim, N.K.4
Valero, V.5
Rosales, M.F.6
-
44
-
-
0242418151
-
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer
-
Baldini E., Gardin G., Giannessi P.G., et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann. Oncol. 14 (2003) 227-232
-
(2003)
Ann. Oncol.
, vol.14
, pp. 227-232
-
-
Baldini, E.1
Gardin, G.2
Giannessi, P.G.3
-
45
-
-
4143106340
-
Dose and time intensified epirubicin/cyclophosphamide (EC) in locally advanced breast cancer
-
(abs 154)
-
Euler U., Dresel V., Bühner M., Volkholz H., and Tulusan A.H.T. Dose and time intensified epirubicin/cyclophosphamide (EC) in locally advanced breast cancer. Breast Cancer Res. Treat. 76 (2002) (abs 154)
-
(2002)
Breast Cancer Res. Treat.
, vol.76
-
-
Euler, U.1
Dresel, V.2
Bühner, M.3
Volkholz, H.4
Tulusan, A.H.T.5
-
46
-
-
0032885642
-
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group
-
Miller K.D., McCaskill-Stevens W., Sisk J., Loesch D.M., Monaco F., Seshadri R., et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J. Clin. Oncol. 17 (1999) 3033-3037
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 3033-3037
-
-
Miller, K.D.1
McCaskill-Stevens, W.2
Sisk, J.3
Loesch, D.M.4
Monaco, F.5
Seshadri, R.6
-
47
-
-
0033060223
-
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel
-
von Minckwitz G., Costa S.D., Eiermann W., Blohmer J.U., Tulusan A.H., Jackisch C., et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J. Clin. Oncol. 17 (1999) 1999-2005
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1999-2005
-
-
von Minckwitz, G.1
Costa, S.D.2
Eiermann, W.3
Blohmer, J.U.4
Tulusan, A.H.5
Jackisch, C.6
-
48
-
-
33750710254
-
Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer
-
Epub ahead of print
-
Cooper B.W., Radivoyevitch T., Overmoyer B.A., Shenk R.R., Pham H.T., Samuels J.R., et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res. Treat. (2005) 1-8 Epub ahead of print
-
(2005)
Breast Cancer Res. Treat.
, pp. 1-8
-
-
Cooper, B.W.1
Radivoyevitch, T.2
Overmoyer, B.A.3
Shenk, R.R.4
Pham, H.T.5
Samuels, J.R.6
-
49
-
-
0038561594
-
Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study
-
abs 133
-
Untch M., Konency G., Ditsch N., et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc. Am. Soc. Clin. Oncol. 21 (2002) 34a abs 133
-
(2002)
Proc. Am. Soc. Clin. Oncol.
, vol.21
-
-
Untch, M.1
Konency, G.2
Ditsch, N.3
-
50
-
-
21044454272
-
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group
-
von Minckwitz G., Raab G., Caputo A., Schutte M., Hilfrich J., Blohmer J.U., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 23 (2005) 2676-2685
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2676-2685
-
-
von Minckwitz, G.1
Raab, G.2
Caputo, A.3
Schutte, M.4
Hilfrich, J.5
Blohmer, J.U.6
-
51
-
-
0020061006
-
Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study
-
Preece P.E., Wood R.A.B., Mackie C.R., and Cuschieri A. Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study. Br. Med. J. 284 (1982) 869-870
-
(1982)
Br. Med. J.
, vol.284
, pp. 869-870
-
-
Preece, P.E.1
Wood, R.A.B.2
Mackie, C.R.3
Cuschieri, A.4
-
52
-
-
0028910481
-
Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease
-
Bergman L., van Dongen J.A., van Ooijen B., and van Leeuwen F.E. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease. Breast Cancer Res. Treat. 34 (1995) 77-83
-
(1995)
Breast Cancer Res. Treat.
, vol.34
, pp. 77-83
-
-
Bergman, L.1
van Dongen, J.A.2
van Ooijen, B.3
van Leeuwen, F.E.4
-
53
-
-
0031006008
-
Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer
-
Willsher P.C., Robertson J.F.R., Jackson L., Al-Hilaly M., and Blarney R.W. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast 6 (1997) 150-154
-
(1997)
Breast
, vol.6
, pp. 150-154
-
-
Willsher, P.C.1
Robertson, J.F.R.2
Jackson, L.3
Al-Hilaly, M.4
Blarney, R.W.5
-
54
-
-
12244294506
-
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
-
Mustacchi G., Ceccherini R., Milani S., Pluchinotta A., De Matteis A., Maiorino L., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann. Oncol. 14 (2003) 414-420
-
(2003)
Ann. Oncol.
, vol.14
, pp. 414-420
-
-
Mustacchi, G.1
Ceccherini, R.2
Milani, S.3
Pluchinotta, A.4
De Matteis, A.5
Maiorino, L.6
-
55
-
-
0142181118
-
-
ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 2003 1802-1810.
-
-
-
-
56
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.S.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
-
57
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004)
-
(2004)
N. Engl. J. Med.
, vol.350
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
Paridaens, R.4
Jassem, J.5
Delozier, T.6
-
58
-
-
3142737587
-
Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: results of a Spanish multicenter phase II trial
-
(abs 603)
-
Gil M.J., Barnadas A., Cirera L., Tusquets I., Muñoz M., Arcusa A., et al. Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: results of a Spanish multicenter phase II trial. Proc. Am. Soc. Clin. Oncol. 23 (2004) (abs 603)
-
(2004)
Proc. Am. Soc. Clin. Oncol.
, vol.23
-
-
Gil, M.J.1
Barnadas, A.2
Cirera, L.3
Tusquets, I.4
Muñoz, M.5
Arcusa, A.6
-
59
-
-
0035692576
-
Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
-
Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12 (2001) 1527-1532
-
(2001)
Ann. Oncol.
, vol.12
, pp. 1527-1532
-
-
Eiermann, W.1
Paepke, S.2
Appfelstaedt, J.3
Llombart-Cussac, A.4
Eremin, J.5
Vinholes, J.6
-
60
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
-
Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001) 3808-3816
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Mauriac, L.4
Llombert-Cussac, A.5
Janicke, F.6
-
61
-
-
10744233578
-
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
-
Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Janicke F., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63 (2003) 6523-6531
-
(2003)
Cancer Res.
, vol.63
, pp. 6523-6531
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Tao, Y.4
Llombart-Cussac, A.5
Janicke, F.6
-
62
-
-
24644490871
-
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
-
Smith I.E., Dowsett M., Ebbs S.R., Dixon M., Skene A., Blohmer J.U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23 (2005) 5108-5116
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5108-5116
-
-
Smith, I.E.1
Dowsett, M.2
Ebbs, S.R.3
Dixon, M.4
Skene, A.5
Blohmer, J.U.6
-
63
-
-
20244374413
-
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a Study from the IMPACT Trialists
-
Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a Study from the IMPACT Trialists. J. Clin. Oncol. 23 (2005) 2477-2492
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2477-2492
-
-
Dowsett, M.1
Ebbs, S.R.2
Dixon, J.M.3
Skene, A.4
Griffith, C.5
Boeddinghaus, I.6
-
64
-
-
33749522748
-
On behalf of the IMPACT Trialists, Ki-67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial
-
(abs 45)
-
Dowsett M., A'Hern R., and Smith I. On behalf of the IMPACT Trialists, Ki-67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Breast Cancer Res. Treat. (2005) (abs 45)
-
(2005)
Breast Cancer Res. Treat.
-
-
Dowsett, M.1
A'Hern, R.2
Smith, I.3
-
65
-
-
27744587240
-
Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER-positive breast cancer patients
-
(abs 2090)
-
Semiglazov V.F., Ivanov V.G., Semiglazov V.V., Ziltsova E.K., Kletzel A.A., Melnikova O.A., et al. Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER-positive breast cancer patients. Breast Cancer Res. Treat. 88 (2004) (abs 2090)
-
(2004)
Breast Cancer Res. Treat.
, vol.88
-
-
Semiglazov, V.F.1
Ivanov, V.G.2
Semiglazov, V.V.3
Ziltsova, E.K.4
Kletzel, A.A.5
Melnikova, O.A.6
-
66
-
-
12144262989
-
Multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer
-
(abs 321)
-
Paepke S., Tulusan A., Kiesel L., Bastert G., Jaenicke F.K., Bouterfa H., et al. Multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (abs 321)
-
(2003)
Proc. Am. Soc. Clin. Oncol.
, vol.22
-
-
Paepke, S.1
Tulusan, A.2
Kiesel, L.3
Bastert, G.4
Jaenicke, F.K.5
Bouterfa, H.6
-
67
-
-
18744395754
-
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: a pilot study
-
Burstein H.J., Harris L.N., Gelman R., Lester S.C., Nunes R.A., Kaelin C.M., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: a pilot study. J. Clin. Oncol. 21 (2003) 46-53
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 46-53
-
-
Burstein, H.J.1
Harris, L.N.2
Gelman, R.3
Lester, S.C.4
Nunes, R.A.5
Kaelin, C.M.6
-
68
-
-
33646376727
-
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
-
Hurley J., Doliny P., Reis I., Silva O., Gomez-Fernandez C., Velez P., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J. Clin. Oncol. 24 (2006) 1831-1838
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1831-1838
-
-
Hurley, J.1
Doliny, P.2
Reis, I.3
Silva, O.4
Gomez-Fernandez, C.5
Velez, P.6
-
69
-
-
3843106892
-
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
-
Wenzel C., Hussian D., Bartsch R., Pluschnig U., Locker G.J., Rudas M., et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J. Cancer Res. Clin. Oncol. 130 (2004) 400-404
-
(2004)
J. Cancer Res. Clin. Oncol.
, vol.130
, pp. 400-404
-
-
Wenzel, C.1
Hussian, D.2
Bartsch, R.3
Pluschnig, U.4
Locker, G.J.5
Rudas, M.6
-
70
-
-
33644683395
-
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
-
Coudert B.P., Arnould L., Moreau L., Chollet P., Weber B., Vanlemmens L., et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann. Oncol. 17 (2006) 409-414
-
(2006)
Ann. Oncol.
, vol.17
, pp. 409-414
-
-
Coudert, B.P.1
Arnould, L.2
Moreau, L.3
Chollet, P.4
Weber, B.5
Vanlemmens, L.6
-
71
-
-
9144241006
-
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results
-
Van Pelt A.E., Mohsin S., Elledge R.M., Hilsenbeck S.G., Gutierrez M.C., Lucci A., et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer 5 (2003) 348-353
-
(2003)
Clin. Breast Cancer
, vol.5
, pp. 348-353
-
-
Van Pelt, A.E.1
Mohsin, S.2
Elledge, R.M.3
Hilsenbeck, S.G.4
Gutierrez, M.C.5
Lucci, A.6
-
72
-
-
21044436148
-
Incorporating trastuzumab into the neoadjuvant treatment of HER2 - Overexpressing breast cancer
-
Montemurro F., and Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2 - Overexpressing breast cancer. Clin. Breast Cancer 6 (2005) 77-80
-
(2005)
Clin. Breast Cancer
, vol.6
, pp. 77-80
-
-
Montemurro, F.1
Aglietta, M.2
-
73
-
-
20544460650
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
-
Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23 (2005) 3676-3685
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 3676-3685
-
-
Buzdar, A.U.1
Ibrahim, N.K.2
Francis, D.3
Booser, D.J.4
Thomas, E.S.5
Theriault, R.L.6
-
74
-
-
33748543404
-
Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study
-
(abs 5049)
-
Buzdar A.U., Valero V., Ibrahim N., Francis D., Theriault R., Green M., et al. Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study. Breast Cancer Res. Treat. (2005) (abs 5049)
-
(2005)
Breast Cancer Res. Treat.
-
-
Buzdar, A.U.1
Valero, V.2
Ibrahim, N.3
Francis, D.4
Theriault, R.5
Green, M.6
-
75
-
-
33847272860
-
-
N.L. Spector, K. Blackwell, J. Hurley, J.L. Harris, D. Lombandi, S. Bacus, et al., EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Proc. Am. Soc. Clin. Oncol. (2006) (abs 502).
-
-
-
-
76
-
-
19944408390
-
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
-
Polychronis A., Sinnett H.D., Hadjiminas D., Singhal H., Mansi J.L., Shivapatham D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. (2005) 383-391
-
(2005)
Lancet Oncol.
, pp. 383-391
-
-
Polychronis, A.1
Sinnett, H.D.2
Hadjiminas, D.3
Singhal, H.4
Mansi, J.L.5
Shivapatham, D.6
-
77
-
-
33749642964
-
Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR + breast cancer
-
(abs 515)
-
Dowsett M., Smith I., Skene A., Llombart A., Mayordomo J., Detre S., et al. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR + breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) (abs 515)
-
(2006)
Proc. Am. Soc. Clin. Oncol.
-
-
Dowsett, M.1
Smith, I.2
Skene, A.3
Llombart, A.4
Mayordomo, J.5
Detre, S.6
-
78
-
-
33847260883
-
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy ± gefitinib with biomarkers evaluation
-
(abs 5048)
-
Guarneri V., Frassoldati A., Ficarra G., Giovannelli S., Borghi F., Puglisi F., et al. Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy ± gefitinib with biomarkers evaluation. Breast Cancer Res. and Treat. 94 (2005) s222 (abs 5048)
-
(2005)
Breast Cancer Res. and Treat.
, vol.94
-
-
Guarneri, V.1
Frassoldati, A.2
Ficarra, G.3
Giovannelli, S.4
Borghi, F.5
Puglisi, F.6
-
79
-
-
33644863001
-
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
-
Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24 (2006) 769-777
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 769-777
-
-
Wedam, S.B.1
Low, J.A.2
Yang, S.X.3
Chow, C.K.4
Choyke, P.5
Danforth, D.6
-
80
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
van de Rijn, M.4
Jeffrey, S.S.5
Rees, C.A.6
-
81
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 1999-2009
-
-
van de Vijver, M.J.1
He, Y.D.2
van't Veer, L.J.3
Dai, H.4
Hart, A.A.5
Voskuil, D.W.6
-
82
-
-
2942729848
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
-
Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22 (2004) 2284-2293
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 2284-2293
-
-
Ayers, M.1
Symmans, W.F.2
Stec, J.3
Damokosh, A.I.4
Clark, E.5
Hess, K.6
-
83
-
-
0042125511
-
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
-
Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
-
(2003)
Lancet
, vol.362
, pp. 362-369
-
-
Chang, J.C.1
Wooten, E.C.2
Tsimelzon, A.3
Hilsenbeck, S.G.4
Gutierrez, M.C.5
Elledge, R.6
-
84
-
-
20044390359
-
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients
-
Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Tham Y.L., et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23 (2005) 1169-1177
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 1169-1177
-
-
Chang, J.C.1
Wooten, E.C.2
Tsimelzon, A.3
Hilsenbeck, S.G.4
Gutierrez, M.C.5
Tham, Y.L.6
-
85
-
-
23844549918
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
-
Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11 (2005) 5678-5685
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 5678-5685
-
-
Rouzier, R.1
Perou, C.M.2
Symmans, W.F.3
Ibrahim, N.4
Cristofanilli, M.5
Anderson, K.6
-
86
-
-
33646339959
-
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer
-
Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24 (2006) 1839-1845
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 1839-1845
-
-
Thuerigen, O.1
Schneeweiss, A.2
Toedt, G.3
Warnat, P.4
Hahn, M.5
Kramer, H.6
-
87
-
-
28044472321
-
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
-
Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23 (2005) 7265-7277
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 7265-7277
-
-
Gianni, L.1
Zambetti, M.2
Clark, K.3
Baker, J.4
Cronin, M.5
Wu, J.6
|